5 completed. 3 Phase 2, 2 Phase 1, 1 Phase 3.
By phase and status
Follow 89bio, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
Pegozafermin, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | 89bio, Inc. | 369 | 2023-06-15 | 2026-07-07 |
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
BIO89-100 - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | 89bio, Inc. | 8 | 2021-08-16 | 2022-03-02 |
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
BIO89-100, Placebo - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Completed | 89bio, Inc. | 222 | 2021-06-04 | 2026-01-06 |
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
Pegozafermin, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | 89bio, Inc. | 86 | 2020-09-01 | 2024-07-25 |
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
Pegozafermin, Placebo - NASH | Phase 1 / Phase 2 | Completed | 89bio, Inc. | 101 | 2019-07-29 | 2024-04-02 |
Conditions studied
Metabolic Diseases (3) · Non-alcoholic Fatty Liver Disease (3) · Dyslipidemias (2) · Fatty Liver (2) · Hypertriglyceridemia (2) · Lipid Metabolism Disorders (2) · Liver Diseases (2) · Digestive System Diseases (1) · Hyperlipidemias (1)
Countries
United States (5) · Puerto Rico (3) · Czechia (2) · Hungary (2) · Poland (2) · Argentina (1) · Austria (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Chile (1) · France (1) · Georgia (1) · Germany (1) · India (1)
Top investigators
Millie Gottwald, PharmD (1) · Teresa Parli, MD (1)
Results publications
PMID 37696614, PMID 36521501, PMID 37355760, PMID 37356033, PMID 37718721
NIH funding
2023 (1)